{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:20:23Z","timestamp":1790094023887,"version":"4.0.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Tumor infiltrating lymphocytes (TIL) drive the anti-tumor activity of a broad class of immunotherapies.\n                      <jats:italic>In situ<\/jats:italic>\n                      TIL are composed of T cells that recognize tumor antigens (Tumor Reactive T cells, or TRTs) as well as bystander T cells with specificity for other antigens. TRT clonotypes are associated with a unique and tumor-driven exhausted transcriptional state, enabling single-cell RNA sequencing (scRNA-seq)-based predictive models for TRTs using experimentally validated clone labels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, a clonotype-level CD8\n                      <jats:sup>+<\/jats:sup>\n                      TRT classifier (TRACE) was built using an aggregated dataset of validated tumor reactive clonotypes and associated scRNA-seq data from multiple publications that overcomes the limitations of training on a single dataset, donor, or indication. TRACE does not require dataset manipulation for training or prediction, enabling it to be easily applied to new test datasets as they emerge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TRACE exhibited robust performance on held-out TIL and PBMC clones - achieving a mean Matthews correlation coefficient of 0.84 and F1-score of 0.85 - comparable to or outperforming other TRT prediction methods. We experimentally confirmed the reactivity of TRACE-identified TRT clones by co-culturing\n                      <jats:italic>ex vivo<\/jats:italic>\n                      expanded TIL with an autologous melanoma tumor cell line. Finally, we applied TRACE to evaluate the frequency of TRTs across hundreds of patient samples from multiple tumor atlases spanning lung, colorectal, and pancreatic cancer. TRACE scores were observed to be significantly higher in exhausted CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in tumors but not in exhausted cells in normal adjacent or non-cancer samples, suggesting specificity towards identifying tumor-antigen experienced T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TRACE is a tumor reactivity scoring algorithm released with open model weights that can be applied to tissue or blood single-cell RNAseq datasets. Its application should be of general interest for characterizing the fraction of TRTs in TIL and for establishing correlations with clinical response to immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1815974","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:24:56Z","timestamp":1776317096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor reactivity assessment using clonal expression reveals tumor reactive CD8+ T cell heterogeneity across solid tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"David","family":"Monteiro","sequence":"first","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Denebeim","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Dodson","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Yeri","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitali","family":"Ghose","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Travers","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Capobianco","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Calnan","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo J.","family":"Martinez","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital","place":["Boston, MA, United States"]},{"name":"Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karrie","family":"Wong","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah J.","family":"Benson","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen","family":"Sangurdekar","sequence":"additional","affiliation":[{"name":"KSQ Therapeutics, Inc.","place":["Lexington, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00335-8","article-title":"Bystander T cells in cancer immunology and therapy","volume":"3","author":"Meier","year":"2022","journal-title":"Nat Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","article-title":"The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer","volume":"56","author":"Chow","year":"2023","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7995","article-title":"Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma","volume":"9","author":"Barras","year":"2024","journal-title":"Sci Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00433-7","article-title":"Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade","volume":"3","author":"Liu","year":"2022","journal-title":"Nat Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"Berg","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01211","article-title":"Selection of shared and neoantigen-reactive T cells for adoptive cell therapy based on CD137 separation","volume":"8","author":"Seliktar-Ofir","year":"2017","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.ccr-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","article-title":"A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers","volume":"40","author":"Hanada","year":"2022","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5447","article-title":"Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers","volume":"375","author":"Lowery","year":"2022","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02232-0","article-title":"Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms","volume":"43","author":"P\u00e9tremand","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55059-3","article-title":"A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types","volume":"16","author":"Zeng","year":"2025","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02161-y","article-title":"Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy","volume":"43","author":"Tan","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2020.04.017","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"181","author":"Li","year":"2020","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna","year":"2021","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh9562","article-title":"Transcriptome-based identification of tumor-reactive and bystander CD8 + T cell receptor clonotypes in human pancreatic cancer","volume":"15","author":"Meng","year":"2023","journal-title":"Sci Transl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41467-022-29175-x","article-title":"Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells","volume":"13","author":"Gao","year":"2022","journal-title":"Nat Commun"},{"key":"B34","unstructured":"Human PBMC from a Healthy Donor, 10k cells (v2)\n          \n          2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1038\/s41467-022-34655-1","article-title":"Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19","volume":"13","author":"Ogura","year":"2022","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01578-0","article-title":"VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2","volume":"19","author":"Goncharov","year":"2022","journal-title":"Nat Methods"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ccell.2022.10.008","article-title":"High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer","volume":"40","author":"Salcher","year":"2022","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00807-z","article-title":"Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms","volume":"5","author":"Chu","year":"2024","journal-title":"Nat Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1440830","article-title":"The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-2183","article-title":"Human pancreatic cancer single-cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells","volume":"31","author":"Loveless","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1012760","article-title":"scRepertoire 2: Enhanced and efficient toolkit for single-cell immune profiling","volume":"21","author":"Yang","year":"2025","journal-title":"PloS Comput Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01088-x","article-title":"Single-cell analyses define a continuum of cell state and composition changes in the Malignant transformation of polyps to colorectal cancer","volume":"54","author":"Becker","year":"2022","journal-title":"Nat Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci163096","article-title":"Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR\/Cas9 screens","volume":"133","author":"Schlabach","year":"2023","journal-title":"J Clin Investig"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.64898\/2026.01.21.700812","article-title":"Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8+ T cell fate to enhance anti-tumor functionality","author":"Mercier","year":"2026"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:24:57Z","timestamp":1776317097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2026.1815974"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1815974","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1815974"}}